Loading...
ANI Pharmaceuticals, Inc.
ANIP•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$67.48
$0.71(1.06%)
ANI Pharmaceuticals, Inc. (ANIP) Financial Performance & Income Statement Overview
Review ANI Pharmaceuticals, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
26.20%
↑ 26.20%
Operating Income Growth
-98.76%
↓ 98.76%
Net Income Growth
-198.63%
↓ 198.63%
Operating Cash Flow Growth
-46.19%
↓ 46.19%
Operating Margin
1.01%
↑ 1.01%
Gross Margin
57.16%
↑ 57.16%
Net Profit Margin
-3.12%
↓ 3.12%
ROE
-4.86%
↓ 4.86%
ROIC
0.63%
↑ 0.63%
ANI Pharmaceuticals, Inc. (ANIP) Income Statement & Financial Overview
Review ANI Pharmaceuticals, Inc.'s (ANIP) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $190.57M | $148.33M | $138.04M | $137.43M |
| Cost of Revenue | $80.28M | $63.08M | $72.39M | $63.84M |
| Gross Profit | $110.29M | $85.26M | $65.64M | $73.59M |
| Gross Profit Ratio | $0.58 | $0.57 | $0.48 | $0.54 |
| R&D Expenses | $16.65M | $10.13M | $7.30M | $10.51M |
| SG&A Expenses | $69.72M | $79.08M | $52.82M | $48.02M |
| Operating Expenses | $114.67M | $105.78M | $60.12M | $58.53M |
| Total Costs & Expenses | $194.95M | $168.85M | $132.51M | $122.38M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | $6.01M | $2.33M | $4.66M | $4.60M |
| Depreciation & Amortization | $22.60M | $15.75M | $14.70M | $14.69M |
| EBITDA | $14.85M | -$13.42M | $23.73M | $29.74M |
| EBITDA Ratio | $0.08 | -$0.09 | $0.17 | $0.22 |
| Operating Income | -$4.38M | -$20.52M | $5.53M | $15.05M |
| Operating Income Ratio | -$0.02 | -$0.14 | $0.04 | $0.11 |
| Other Income/Expenses (Net) | -$9.38M | -$10.98M | -$7.46M | $10.28M |
| Income Before Tax | -$13.76M | -$31.50M | -$2.29M | $25.34M |
| Income Before Tax Ratio | -$0.07 | -$0.21 | -$0.02 | $0.18 |
| Income Tax Expense | -$3.49M | -$7.33M | $0.00 | $7.13M |
| Net Income | -$10.28M | -$24.17M | -$2.29M | $18.21M |
| Net Income Ratio | -$0.05 | -$0.16 | -$0.02 | $0.13 |
| EPS | -$0.55 | -$1.27 | -$0.12 | $0.84 |
| Diluted EPS | -$0.55 | -$1.27 | -$0.12 | $0.83 |
| Weighted Avg Shares Outstanding | $19.45M | $19.40M | $19.32M | $19.10M |
| Weighted Avg Shares Outstanding (Diluted) | $19.45M | $19.40M | $19.32M | $19.42M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan